Reprogramming the stem cell for a new generation of cures

Although tremendous progress has been made over the last few decades, cell therapies today are expensive and not particularly scalable.

The development of new drugs has not kept up with the progress in biology. The majority of clinical trials fail because the drugs are either toxic or they do not work in human diseases. Human biology often proves to be distinct and sufficiently different from animal models and associated cell lines used for drug development. Widespread access to reliable human cells is needed to replace suboptimal disease and drug response models the industry currently relies on to enable a new generation of medicine.